CMS Approves Separate Medicare Payment for InfuSystem Infusion Pumps Under NOPAIN Act
InfuSystem Holdings Inc. announced that the Centers for Medicare and Medicaid Services $(CMS)$ has added two electronic infusion pumps used by the company-ICU Medical's CADD-SolisTM and Eitan Medical's SapphireTM-to the list of products qualifying for separate payment under the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act. This CMS decision allows InfuSystem's current and potential Pain Management customers to receive separate reimbursement for these devices when used with covered surgical procedures, starting January 1, 2026, through December 31, 2027. The NOPAIN Act initiative is aimed at promoting non-opioid alternatives for pain management and reducing opioid use in postoperative care. The approval covers products from multiple manufacturers, not just InfuSystem.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InfuSystem Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-056364), on December 10, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。